{"commentary":{"count":8,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":4,"podcast":3,"x_thread":1},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04115631\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"NCT04115631","nct_id":"NCT04115631","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct04115631. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":null,"arms":[{"description":"Patients receive bendamustine IV on days 1 and 2 and rituximab IV on day 1 or 2. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Beginning cycle 4, patients receive rituximab IV on day 1 and cytarabine IV every Q12 hours on days 1 and 2. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.","label":"Arm A (bendamustine, rituximab, cytarabine)","type":"EXPERIMENTAL"},{"description":"Patients receive PO BID on days 1-28, bendamustine IV on days 1 and 2, and rituximab IV on day 1 or 2. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Beginning cycle 4, patients receive acalabrutinib PO BID on days 1-7 and 22-28, rituximab IV on day 1, and cytarabine IV Q12 hours on days 1 and 2. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.","label":"Arm B (acalabrutinib, bendamustine, rituximab, cytarabine)","type":"EXPERIMENTAL"},{"description":"Patients receive acalabrutinib PO BID on days 1-28, bendamustine IV on days 1 and 2, and rituximab IV on day 1 or 2. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.","label":"Arm C (acalabrutinib, bendamustine, rituximab)","type":"EXPERIMENTAL"}],"collaborators":["National Cancer Institute (NCI)"],"completion_date":{"date":"2026-12-31","type":"ESTIMATED"},"conditions":["Liver Lymphoma","Mantle Cell Lymphoma"],"enrollment":{"count":360,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Acalabrutinib","type":"DRUG"},{"name":"Bendamustine","type":"DRUG"},{"name":"Bendamustine Hydrochloride","type":"DRUG"},{"name":"Cytarabine","type":"DRUG"},{"name":"Rituximab","type":"BIOLOGICAL"}],"last_update":"2026-09-14","lead_sponsor":"ECOG-ACRIN Cancer Research Group","official_title":"A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CR-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients &lt;/= 70 Years Old With Untreated Mantle Cell Lymphoma","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2026-12-31","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Composite of positron emission tomography (PET)/computed tomography (CT) complete response (CR) and peripheral blood (PB) minimal residual disease (MRD) negative rate","timeFrame":"Up to 8 weeks post treatment"}],"references":[{"citation":"Patel DA, Wan F, Trinkaus K, Guy DG, Edwin N, Watkins M, Bartlett NL, Cashen A, Fehniger TA, Ghobadi A, Shah NM, Kahl BS. Bendamustine/Rituximab Plus Cytarabine/Rituximab, With or Without Acalabrutinib, for the Initial Treatment of Transplant-Eligible Mantle Cell Lymphoma Patients: Pooled Data From Two Pilot Studies. Clin Lymphoma Myeloma Leuk. 2023 Jul;23(7):552-560. doi: 10.1016/j.clml.2023.04.003. Epub 2023 Apr 24.","pmid":"37183115","type":"DERIVED"}],"start_date":{"date":"2019-12-13","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma","url":"https://clinicaltrials.gov/study/NCT04115631"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct04115631"}